NK vs. PRME, PLX, IKT, IZTC, CVM, ZIVO, JATT, CRTX, ALVR, and FNCH
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), Cortexyme (CRTX), AlloVir (ALVR), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
NantKwest vs. Its Competitors
Prime Medicine (NYSE:PRME) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Prime Medicine currently has a consensus price target of $8.92, suggesting a potential upside of 56.98%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Prime Medicine is more favorable than NantKwest.
NantKwest has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.
Prime Medicine has a net margin of 0.00% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Prime Medicine's return on equity.
Prime Medicine has a beta of 2.65, suggesting that its share price is 165% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its share price is 161% more volatile than the S&P 500.
In the previous week, Prime Medicine had 4 more articles in the media than NantKwest. MarketBeat recorded 4 mentions for Prime Medicine and 0 mentions for NantKwest. Prime Medicine's average media sentiment score of 0.63 beat NantKwest's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.
Summary
Prime Medicine beats NantKwest on 11 of the 17 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
This page (NASDAQ:NK) was last updated on 10/10/2025 by MarketBeat.com Staff
